Roche announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting from December 3-6 in San Diego. The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.
“The breadth of data we are presenting at ASH this year reflects our deep commitment to people with blood diseases,” said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. “We are excited to share the results of the pivotal GALLIUM study in previously untreated follicular lymphoma, which showed that people treated with Gazyva/Gazyvaro plus chemotherapy lived significantly longer without their disease worsening than those treated with Rituxan/MabThera plus chemotherapy.”
The results from the phase III GALLIUM study have been selected for presentation during the Plenary Scientific Session, which honours the top six abstracts submitted to the meeting, as determined by the ASH Program Committee. Results from other studies of Gazyva®/Gazyvaro1 will also be presented at the meeting, including an overall survival update from the phase III GADOLIN study in Rituxan®/MabThera®2 -refractory indolent (slow-growing) non-Hodgkin lymphoma (NHL) and the first results from the phase III GOYA study in previously untreated diffuse large B-cell lymphoma (DLBCL).
Updated results from the phase III SABRINA study comparing subcutaneous and intravenous Rituxan/MabThera in previously untreated follicular lymphoma will be presented. The US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the subcutaneous formulation of Rituxan, with an action date of June 26, 2017.
Early results will be shared for combinations of Venclexta/Venclyxto with either Gazyva/Gazyvaro or Rituxan/MabThera in chronic lymphocytic leukaemia and certain types of non-Hodgkin lymphoma. Further follow-up from early studies in multiple myeloma and acute myeloid leukaemia that support further investigation of Venclexta/Venclyxto in these diseases will also be presented. Venclexta/Venclyxto is being co-developed by AbbVie and Roche.
The first cohort from a non-interventional study of people with haemophilia will be presented, including real world safety and efficacy data from patients with inhibitors to factor VIII replacement therapy treated with current standard of care according to routine clinical practice. Separately, there are currently three pivotal studies underway to explore the safety and efficacy of emicizumab3 in the treatment of haemophilia A: a phase III study in people 12 years of age or older with haemophilia A with factor VIII inhibitors investigating weekly dosing; a phase III study in people younger than 12 years of age with factor VIII inhibitors investigating weekly dosing; and a phase III study in people 12 years of age or older without factor VIII inhibitors investigating weekly and every other week dosing.
